Cutting edge: IL-1β mediates the proangiogenic activity of osteopontin-activated human monocytes

Journal of Immunology

Volumn 177, Issue 7, 2006, Pages 4267-4270

  Naldini, Antonella ^a   Leali, Dana ^b   Pucci, Annalisa ^a   Morena, Emilia ^a   Carraro, Fabio ^a   Nico, Beatrice ^c   Ribatti, Domenico ^c   Presta, Marco ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUTRALIZING ANTIBODY; OSTEOPONTIN; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL ACTIVATION; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME PHOSPHORYLATION; INFLAMMATION; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SUPERNATANT; UPREGULATION;

EID: 33749151344     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.7.4267     Document Type: Article

References (30)

1. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.
2. Kerbel, R., and J. Folkman. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2: 727-739.
3. Lingen, M. W. 2001. Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing. Arch. Pathol. Lab. Med. 125: 67-71.
4. O'Reilly, M. S., T. Boehm, Y. Shing, N. Fukai, G. Vasios, W. S. Lane, E. Flynn, J. R. Birkhead, B. R. Olsen, and J. Folkman. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
5. Voronov, E., D. S. Shouval, Y. Krelin, E. Cagnano, D. Benhartoch, Y. Iwakura, C. A. Dinarello, and R. N. Apte. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100: 2645-2650.
6. Bar, D., R. N. Apte, E. Voronov, C. A. Dinarello, and S. Cohen. 2004. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J. 18: 161-163.
7. O'Regan, A. W., G. J. Nau, G. L. Chupp, and J. S. Berman. 2000. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol. Today 21: 475-478.
8. Denhatdt, D. T., M. Noda, A. W. O'Regan, D. Pavlin, and J. S. Berman. 2001. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107: 1055-1061.
9. Rittling, S. R., Y. Chen, F. Feng, and Y. Wu. 2002. Tumor-derived osteopontin is soluble, not matrix associated. J. Biol. Chem. 277: 9175-9182.
10. Denhardt, D. T., D. Mistretta, A. F. Chambers, S. Krishna, J. F. Porter, S. Raghuram, and S. R. Rittling. 2003. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin. Exp. Metastasis 20: 77-84.
11. Leali, D., P. Dell'Eta, H. Stabile, B. Sennino, A. F. Chambers, A. Naldini, S. Sozzani, B. Nico, D. Ribatti, and M. Presta. 2003. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J. Immunol. 171: 1085-1093.
12. Zhu, B., K. Suzuki, H. A. Goldberg, S. R. Rittling, D. T. Denhardt, C. A. McCulloch, and J. Sodek. 2004. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J. Cell. Physiol. 198: 155-167.
13. Xu, G., H. Nie, N. Li, W. Zheng, D. Zhang, G. Feng, L. Ni, R. Xu, J. Hong, and J. Z. Zhang. 2005. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J. Clin. Invest. 115: 1060-1067.
14. Yumoto, K., M. Ishijima, S. R. Rittling, K. Tsuji, Y. Tsuchiya, S. Kon, A. Nifuji, T. Uede, D. T. Denhardt, and M. Noda. 2002. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc. Natl. Acad. Sci. USA 99: 4556-4561.
15. Ribatti, D., B. Nico, A. Vacca, and L. Roncali. 1999. Localization of factor VIII-related antigen in the endothelium of the chick embryo chorioallantoic membrane. Histochem. Cell Biol. 112: 447-450.
16. Ribatti, D., A. Gualandris, M. Bastaki, A. Vacca, M. Iurlaro, L. Roncali, and M. Presta. 1997. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J. Vasc. Res. 34: 455-463.
17. Kyriakis, J. M., and J. Avruch. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81: 807-869.
18. Dinarello, C. A. 1998. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16: 457-499.
19. Hellwig-Burgel, T., K. Rutkowski, E. Metzen, J. Fandtey, and W. Jelkmann. 1999. Interleukin-1β and tumor necrosis factor α stimulate DNA binding of hypoxia-inducible factor-1. Blood 94: 1561-1567.
20. Jung, Y. J., J. S. Isaacs, S. Lee, J. Trepel, and L. Neckers. 2003. IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17: 2115-2117.
21. Calvani, M., A. Rapisarda, B. Uranchimeg, R. H. Shoemaker, and G. Melillo. 2006. Hypoxic induction of an HIF-1α-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107: 2705-2712.
22. Giachelli, C. M., D. Lombardi, R. J. Johnson, C. E. Murry, and M. Almeida. 1998. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol. 152: 353-358.
23. Yoshitake, H., S. R. Rittling, D. T. Denhardt, and M. Noda. 1999. Osteopomin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc. Natl. Acad. Sci. USA 96: 8156-8160.
24. Ashkar, S., G. F. Weber, V. Panoutsakopoulou, M. E. Sanchirico, M. Jansson, S. Zawaideh, S. R. Rittling, D. T. Denhardt, M. J. Glimcher, and H. Cantor. 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287: 860-864.
25. Liaw, L., D. E. Birk, C. B. Ballas, J. S. Whitsitt, J. M. Davidson, and B. L. Hogan. 1998. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Invest. 101: 1468-1478.
26. Dinarello, C. A. 2000. Proinflammatory cytokines. Chest 118: 503-508.
27. Jackson, J. R., M. P. Seed, C. H. Kircher, D. A. Willoughby, and J. D. Winkler. 1997. The codependence of angiogenesis and chronic inflammation. FASEB J. 11: 457-465.
28. Sunderkotter, C., K. Steinbrink, M. Goebeler, R. Bhardwaj, and C. Sorg. 1994. Macrophages and angiogenesis. J. Leukocyte Biol. 55: 410-422.
29. Leibovich, S. J., P. J. Polverini, H. M. Shepard, D. M. Wiseman, V. Shively, and N. Nuseir. 1987. Macrophage-induced angiogenesis is mediated by tumour necrosis factor α. Nature 329: 630-632.
30. Asou, Y., S. R. Rittling, H. Yoshitake, K. Tsuji, K. Shinomiya, A. Nifuji, D. T. Denhardt, and M. Noda. 2001. Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 142: 1325-1332.